|
Octreotide acetate
drug data and news
Octreotide acetate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Octreotide acetate
|
| Brand Names/Synonyms |
Sandostatin LAR; Sandostatin LAR |
| Indication |
For treatment of acromegaly and reduction of side effects from cancer chemotherapy |
|
Sponsored links
|
|
Description |
Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. |
| Pharmacology |
Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly. |
| Mechanism Of Action |
Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins. |
Octreotide acetate News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
SOLUTION |
| Drug_Category |
Hormone replacement; Anabolic Agents; unclassified therapeutic agents (92:00.00) |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
Octreotide acetate |
| Chemical Formula |
C49H66N10O10S2.2C2H4O2 |
| Molecular Weight |
1138.4822 |
| Smiles String |
Not Available |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Transparent, slightly viscous, aqueous liquid |
| LogP/Hphobicity |
Not Available |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.rxlist.com/cgi/generic2/octreotide.htm |
| Drug Type |
Approved Drug |
| Accession No |
BIOD00088 |
| CAS Registry Number |
83150-76-9 |
| KEGG Compound ID |
C07306 |
| PubChem ID |
9514 |
| PharmGKB ID |
PA450679 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
2248639
|
|
|
